Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond.
作者信息
Chen Lanyi Nora, Carvajal Richard D
机构信息
Columbia University Medical Center, New York, NY, USA.
Northwell Health Cancer Institute, New Hyde Park, NY, USA.
出版信息
Ann Transl Med. 2023 Aug 30;11(10):368. doi: 10.21037/atm-23-839. Epub 2023 Mar 13.
Abstract
摘要
相似文献
1
Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond.II期黑色素瘤辅助免疫治疗的考量：KEYNOTE-716及其他进展
Ann Transl Med. 2023 Aug 30;11(10):368. doi: 10.21037/atm-23-839. Epub 2023 Mar 13.
2
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.KEYNOTE-716：帕博利珠单抗辅助治疗与安慰剂用于 II 期高危黑色素瘤切除术后的 III 期研究。
Future Oncol. 2020 Jan;16(3):4429-4438. doi: 10.2217/fon-2019-0666. Epub 2019 Dec 24.
3
Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews.辅助免疫治疗推荐用于 III 期黑色素瘤：医生和护士访谈。
BMC Cancer. 2021 Sep 10;21(1):1014. doi: 10.1186/s12885-021-08752-1.
4
Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises.澳大利亚高风险可切除黑色素瘤的治疗：现状与实践。
Australas J Dermatol. 2020 Aug;61(3):203-209. doi: 10.1111/ajd.13309. Epub 2020 May 13.
5
Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners.我是否应该接受辅助免疫治疗？一项针对接受手术切除的 III 期黑色素瘤成人及其伴侣的访谈研究。
Patient. 2021 Sep;14(5):635-647. doi: 10.1007/s40271-021-00507-1. Epub 2021 Mar 24.
6
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.帕博利珠单抗辅助治疗与安慰剂治疗切除后的高危II期黑色素瘤：3期随机KEYNOTE-716研究中的健康相关生活质量
Eur J Cancer. 2022 Nov;176:207-217. doi: 10.1016/j.ejca.2022.08.004. Epub 2022 Oct 3.
7
Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions.早期非小细胞肺癌患者的辅助免疫治疗及未来方向。
Curr Treat Options Oncol. 2022 Dec;23(12):1721-1731. doi: 10.1007/s11864-022-01034-3. Epub 2022 Dec 1.
8
Fallen dogmas: recent advances in locoregionally advanced melanoma.颠覆旧识：局部晚期黑色素瘤的最新进展。
Pol Arch Intern Med. 2021 May 25;131(5):464-468. doi: 10.20452/pamw.15936. Epub 2021 Apr 14.
9
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.帕博利珠单抗对比安慰剂作为 IIB 期或 IIC 期黑色素瘤（KEYNOTE-716）的辅助治疗：一项多中心、双盲、随机、III 期试验的无远处转移生存结果。
Lancet Oncol. 2022 Nov;23(11):1378-1388. doi: 10.1016/S1470-2045(22)00559-9. Epub 2022 Oct 18.
10
Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.恶性黑色素瘤的辅助治疗及前哨淋巴结定位的作用。
Recent Results Cancer Res. 2000;157:178-89. doi: 10.1007/978-3-642-57151-0_15.
引用本文的文献
1
Adjuvant Immunotherapy in Stage IIB/IIC Melanoma: Current Evidence and Future Directions.IIB/IIC期黑色素瘤的辅助免疫治疗：当前证据与未来方向
Biomedicines. 2025 Aug 4;13(8):1894. doi: 10.3390/biomedicines13081894.
本文引用的文献
1
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.帕博利珠单抗对比安慰剂作为 IIB 期或 IIC 期黑色素瘤（KEYNOTE-716）的辅助治疗：一项多中心、双盲、随机、III 期试验的无远处转移生存结果。
Lancet Oncol. 2022 Nov;23(11):1378-1388. doi: 10.1016/S1470-2045(22)00559-9. Epub 2022 Oct 18.
2
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.根据在美国两个独立队列中验证的第 8 版美国癌症联合委员会（AJCC）分期，Ⅰ期和Ⅱ期原发性黑色素瘤患者的预后：辅助治疗的意义。
J Clin Oncol. 2022 Nov 10;40(32):3741-3749. doi: 10.1200/JCO.22.00202. Epub 2022 Jun 16.
3
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.帕博利珠单抗对比安慰剂作为完全切除的IIB期或IIC期黑色素瘤辅助治疗（KEYNOTE-716）：一项随机、双盲、3期试验
Lancet. 2022 Apr 30;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. Epub 2022 Apr 1.
4
Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice.黑色素瘤的预后基因表达谱分析：纳入临床实践的必要步骤。
Melanoma Manag. 2019 Dec 17;6(4):MMT32. doi: 10.2217/mmt-2019-0016.
5
Considering adjuvant therapy for stage II melanoma.考虑辅助治疗 II 期黑色素瘤。
Cancer. 2020 Mar 15;126(6):1166-1174. doi: 10.1002/cncr.32585. Epub 2019 Dec 23.
6
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的 5 年生存数据
N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.
7
Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.帕博利珠单抗用于美国高风险 III 期黑色素瘤辅助治疗的成本效果分析。
J Med Econ. 2019 Oct;22(10):981-993. doi: 10.1080/13696998.2019.1609485. Epub 2019 May 17.
8
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.帕博利珠单抗辅助治疗与安慰剂对照用于 III 期黑色素瘤完全切除术后患者的随机、双盲、III 期临床试验
N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.
9
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.在 523 例皮肤黑素瘤患者的独立队列中评估预后 31 基因表达谱的性能。
BMC Cancer. 2018 Feb 5;18(1):130. doi: 10.1186/s12885-018-4016-3.
10
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.黑色素瘤分期：美国癌症联合委员会第八版癌症分期手册中基于证据的变化。
CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.
Zotero 插件